Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Forever Young International (operating as Forever Young Health) is a UK-based consumer healthcare and nutraceutical company specializing in scientifically formulated live bacteria and probiotic supplements. The company is best known for its flagship brand, Probio7, which offers a range of high-quality probiotic and prebiotic products designed to support gut health, digestion, and immune function. Founded in 1995, the company was acquired by Samarkand Group in 2017 and subsequently sold to Covestus in June 2024 for £1.3 million. Forever Young International's products, such as Probio7 Advanced and Probio7 Ultra, utilize clinically researched bacterial strains to address common digestive issues like IBS, bloating, and constipation.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Forever Young Health.